Subscription Center
Aug 18, 2008 04:07 PM
On Friday, the U.S. Food and Drug Administration approved the first-ever treatment for Huntington's disease—the crippling illness that killed folksinger Woody Guthrie and that plagues 30,000 Americans.
Tetrabenazine, known commercially as Xenazine, was originally developed in the 1950s to treat symptoms of psychosis. It's not a cure-all for sufferers of the disease. Rather, it addresses a primary symptom of Huntington's—which is seen in 90 percent of patients: involuntary, spastic movements. According to a 2006 study, researchers at the University of Rochester Medical Center were able to reduce these movements in 54 patients by an average of 25 percent.
Huntington's disease is a genetic disorder that can be diagnosed with a simple blood test. Typically, people who inherit one or more of these disrupted genes from their parents will live normally until their 30s or 40s, when brain cells in areas linked to functions such as movement begin to die off. In addition to the sudden, involuntary movements, sufferers also experience mental difficulties, depression and changes in their personality. Eventually, the illness results in death—in many cases by suicide because of the suffering form the disease.
The drug is not without side effects: It may heighten depression and cause the body to stiffen up. But, as Rochester neurologist Frederick Marshall notes in a press statement, while tetrabenazine won't cure Huntington's, it allows sufferers to enjoy a better quality of life—with some patients able to return to the activities they enjoy after spending years homebound.
Tags:
Xenazine,
FDA,
chorea,
Tetrabenazine,
Huntington's disease
More News Blog:
Next: Olympics king Michael Phelps gets ready to conquer Facebook
Previous: Peak water crisis dominates World Water Week
See what we're tweeting about
BecCrew I have no idea what this means but I love it so much http://t.co/NA5WMMApWS
DNLee5 #DispatchesDNLee: Non-target capture Marsh Mongoose: http://t.co/h6iOKMW63v via @YouTube
Horganism Ahab to severed whale head: O head! thou hast seen enough to split the planets and make an infidel of Abraham and not one syllable is thine!
Deadline: Jun 30 2013
Reward: $1,000,000 USD
This is a Reduction-to-Practice Challenge that requires written documentation and&
Deadline: Jul 25 2013
Reward: Varies
This challenge provides an opportunity for Solvers to build a web-based or mobile “app” to explore data relationships in scholarly conte
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
Comments
Add Comment